Dr. Hongtao Hu 胡鸿涛
Chief Physician
Department of Minimally Invasive Intervention, Henan Cancer Hospital, Zhengzhou
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Vascular interventional oncology, gastrointestinal stenting, and CT-guided tumor ablation.
Dr. Hu is Deputy Director of the Minimally Invasive Intervention Department and a Chief Physician at Henan Cancer Hospital. Dr. Hu holds a doctoral degree and serves as a master’s supervisor.
Professional roles
- Member, Chinese Medical Association
- Standing Committee Member and Secretary, Tumor Ablation Professional Committee, China Anti-Cancer Association
- Youth Committee Member, Radiology Branch, Chinese Medical Association
- Youth Committee Member, Tumor Intervention Committee, China Anti-Cancer Association
Name order: in Chinese the family name comes first (Hu Hongtao). Papers usually list the name as Hongtao Hu or Hu H.
Selected publications
67 papers on PubMed matched by name and affiliation; 22 as first or senior author since 2016. Most recent first- or senior-author papers:
- Int J Nanomedicine, 2026 (senior author): Nanoplatform-Enhanced Therapies for Adenoid Cystic Carcinoma: Integrating Pathobiology, Microenvironment Modulation, and Synergistic Treatment Strategies. PubMed 42979196
- ACS Appl Mater Interfaces, 2026 (senior author): A Biomimetic Mn-Doped Polydopamine Nanoplatform for MRI-Enabled Synergistic Therapy to Enhance Lenvatinib Efficacy in Liver Cancer. PubMed 42003816
- JMIR Cancer, 2026 (senior author): Co-Ablation System for Pain Management in Bone Metastases: Retrospective Exploratory Study. PubMed 41711392
- Front Oncol, 2025 (senior author): TACE combined with regorafenib with or without anti-PD-1 therapy for advanced HCC after targeted therapy failure: a multicenter real-world study. PubMed 41179689
- J Hepatocell Carcinoma, 2025 (senior author): MRI-Based Deep Learning and Radiomics Nomogram for Predicting Hepatocellular Carcinoma Recurrence Within Six Months After Thermal Ablation. PubMed 41080630
- Front Immunol, 2025 (senior author): Efficacy and safety of DEB-TACE combined with transarterial TQB2450 infusion and oral Anlotinib as first-line treatment in advanced hepatocellular carcinoma: a single-arm phase II study. PubMed 40959056
- Front Oncol, 2025 (senior author): Transarterial chemoembolization combined with apatinib in the treatment of advanced hepatocellular carcinoma: a prospective, multi-center, real-world study (Ahend-HAP02). PubMed 40678062
- BMC Gastroenterol, 2024 (senior author): Correction: The important role of whole-process computed tomography guidance for percutaneous gastrostomy in esophageal cancer patients who are unsuitable for or have had unsuccessful attempts with endoscopic and fuoroscopic gastrostomy. PubMed 38408889
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion